Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th World Congress on Cancer Therapy Atlanta, Georgia, USA.

Day 1 :

Keynote Forum

Jack C. Westman

University of Wisconsin School of Medicine and Public Health, USA

Keynote: A Review of Cancer Immunotherapies and Nutritional Therapies

Time : 08:50-09:15

Conference Series Cancer Therapy 2015 International Conference Keynote Speaker Jack C. Westman photo

Jack C. Westman completed an M.D. and an M.S. at the University of Michigan. He is an Emeritus Professor at the University of Wisconsin School of Medicine and Public Health. He has published more than 160 professional articles and 12 books. He has served as president of three professional organizations and currently is the president of Wisconsin Cares, Inc..


Immunotherapies and nutritional therapies are assuming prominence in the prevention and treatment of cancer. \\\\r\\\\n\\\\r\\\\nImmunoediting is the process in which aberrant cells multiply. Immunosurveillance by the immune system distinguishes between aberrant and normal cells and usually eradicates aberrant cells. Some aberrant cells withstand immunosurveillance and may become benign tumors. Some aberrant cells grow unrestrained by immunosurveillance and become cancer cells in the neoplastic process. Immunotherapies can be classified as: 1) active that stimulates a patient’s innate immune response; 2) adoptive that exposes immune system cells to specific cancer antigens; 3) restorative that restores deficient functions of immune system cells without removing them from a patient; and 4) passive that infuses a patient with antibodies to antigens on the patient’s cancer cells. The evidence suggests that a combination of immunotherapies most closely resembles the way in which the immune system works. By 2013, thirteen immunotherapy antibodies had been approved by the FDA, and many more are currently being evaluated in clinical trials.\\\\r\\\\n\\\\r\\\\nNutritional therapies include 1) the ketogenic diet that starves cancer cells; 2) CELLFOOD that produces an alkaline body and high levels of oxygen that smother cancer cells; 3) curcumin that inhibits tumor growth and metastasis; 4) IAHCC that is an immune system modulator, 5) milk thistle that stimulates detoxification pathways and inhibits the growth of cancer cells; and 6) vitamin D3 that can prevent the formation of and kill cancer cells. The most effective approach is to use all of them as a “cocktail”.\\\\r\\\\n

Keynote Forum

Erwin G Van Meir

Emory University,USA

Keynote: BAI1 is a brain-specific tumor suppressor

Time : 09:15-09:40

Conference Series Cancer Therapy 2015 International Conference Keynote Speaker Erwin G Van Meir photo

Dr. Van Meir has completed his PhD from the University of Lausanne, Switzerland and postdoctoral studies from the Ludwig Institute for Cancer Research, La Jolla, CA. He is the leader of the cancer cell biology program at the Winship Cancer Institute, an NCI-designated Cancer Center. He has published over 150 manuscripts in peer-reviewed international journals and these have been cited over 15,000 times


Brain-specific Angiogenesis Inhibitor 1 (BAI1) is a seven transmembrane G protein-coupled receptor (GPCR), and we have previously shown that it has potent anti-angiogenic and anti-tumorigenic properties in gliomas.1-6 We now found that BAI1 expression is reduced in human medulloblastoma (MB) by epigenetic mechanisms, involving methylated DNA binding protein MBD2 and histone methylase EZH2. Restoration of BAI1 expression reduced MB cell proliferation and tumor growth in mice xenografts. Targeting MBD2 and EZH2 with small molecules reactivated BAI1 expression, and suppressed tumor growth, supporting the use of epigenetic therapeutics against MB. To more directly examine whether loss of BAI1 expression may favor tumor development during cerebellar development, we generated a Bai1 knockout (KO) mouse.7 We detected a thicker external granular layer (EGL) during early postnatal cerebellum development, which was accompanied by increased proliferation in cGNPs and aberrant activation of Sonic hedgehog signaling. Bai1 loss was not sufficient to initiate tumorigenesis per se, but dramatically accelerated MB tumorigenesis when crossed to mice heterozygous for patched 1 (ptc1+/-), and we will present some of the underlying mechanisms. Altogether, our findings provide insight into the physiological function of BAI1 in the brain, in particular the suppression of medulloblastoma formation in the cerebellum.

Conference Series Cancer Therapy 2015 International Conference Keynote Speaker Yoshiaki Omura photo


Introduction: Non-invasive, quick diagnosis of cancer and their safe, effective individualized treatment will be presented. Methods:Using simple, non-invasiveElectro-Magnetic Field Resonance Phenomenon between 2 identical molecules which received a U.S. patent in 1993, we analyze completed Mouth, Hand, and Footwriting Form, to detect most malignancies & their metastasis at any part of the body long before standard laboratory tests can detect any malignancies. For treatment, before using any treatment, we used an average adult optimal dose of 400 I.U. Vitamin D3. Our latest discovery is diagnosis of cancer from the QRS complex of an ECG.Results: We treated over 100 patients, most of them who had a significant reduction of cancer parameters, including Oncogen C-fos Ab2 &Integrin α5β1 (to less than 1/1000), and 8-OH-dG (which is proportional to DNA mutations to 1/5~1/10). If Integrinα5β1 is less than 100 ng, standard laboratory tests often cannot detect a malignancy. The most optimal, effective dose of any treatment was individually determined by using above method. Average optimal dose of Vitamin D3400IU for adult not only inhibit cancer activity markedly but also often increased extremely low Acetylcholine and DHEA levels to normal level. Cancer activity & associated symptoms significantly reduced without any side effects in more than 85% of patients. However, commonly used 2000~5000IU Vitamin D3 significantly promote cancer activities more than 2 times.Discussion: In the remaining 15% of patients we found that what patients were eating, drinking, and wearing affected their treatment. Since most patients made significant improvements, before using any other cancer treatment, we recommended to see the result of initialoptimal dose of Vitamin D3treatment. We found the optimal dose also depends on their age & the degree of patients physical activity, while standard methods of estimating dose requirements are proportional to body weight.

Keynote Forum

Michael Weber

Laser Clinic Dr. Weber, Germany

Keynote: Systemic and interstitial photodynamic laser therapy: New options in oncology

Time : 10:15-10:40

Conference Series Cancer Therapy 2015 International Conference Keynote Speaker Michael Weber photo

Michael Weber is a medical practitioner for more than 20 years in Germany and leader of three medical centers for general and internal medicine, pain and cancer treatment.rnFurthermore he is a certifi ed bio-chemist and medical doctor. He is working in research with many national and International institutions and universities. He is president of thernInternational society for Medical Laser applications and editor in chief of the Inter-national Journal for Medical Laser Applications. He is also Co-editor of several other journals.


Photodynamic therapy is one of the most interesting and promising approaches in the treatment of various cancers. Treatmentsrnare easy to perform and – in contrast to chemotherapy – normally without severe side-eff ects. Th e principle is the stimulationrnof a light-sensitive drug which is injected into the blood. Th rough endocytosis, the photosensitizer binds to tumour cells anywherernin the body with high specifi city. Th e process takes several hours and tumour cells will have turned light sensitive at the end.rnTumour tissue is subsequently destroyed by irradiation with light of appropriate wavelength according to the absorption spectra ofrnthe various photosensitizers. Th e basic principle behind this mechanism is the development of radical oxygen species.rnIn contrast to traditional chemotherapy PDT does not only destroy cancer cells by oxygen radicals but also initiates a lotrnof diff erent reactions in the treated area with a stimulation of the immune system (PDT-immunisation). Photosensitizers arernmostly porphyrin molecules and derivatives either from the human heme (without the iron atom) or plantderived chlorophyllrn(without the magnesium atom). Accordingly, they are called hematoporphyrins or chlorines. Some are already approved and usedrnin therapy, e.g. Photofrin for treatment of early stage bronchial and gastric cancer.rnRed (in most cases), blue or yellow light is used for light activation of photosensitizers either from outside or through anrnendoscope. Due to the limited penetration depth of light eff ective photosensitizer stimulation and tumour destruction can onlyrnbe achieved at the surface of the skin or in the tissue just a few centimetres underneath the skin. An eff ective treatment of deeprntumours or metastases (e.g. liver cancer or lymph nodes) has normally not been possible and therapeutic applications have so farrnbeen primarily used to treat dermatological tumours. Due to this limitation, progress has been slow until recently.rnToday, new technological developments that facilitate systemic and interstitial photodynamic therapies overcome this barrierrnand constitute the basis for massive growth in the fi eld. Th e lecture will focus on presenting the new technology of systemic andrninterstitial photodynamic laser therapy, newest photosensitizers (with very specifi ty and low side-eff ects) and clinical results fromrnthe last few years of research and development in Germany.